Tilray does not rest until it has reached great levels of innovation, and it is something that can be seen week after week. The world’s number one cannabis company announced today that its division, Tilray Medical, has launched new products for all consumers in this market. In addition to these products that will work under the Aphria and Tilray brands, it has launched CannaPoints, a new program aimed at supporting patients in their medical cannabis adventure.
Blair MacNeil, president of Tilray Canada, said he and his team are extremely proud to have done what it takes to bring their portfolio of cannabis products to new heights in Canada. Expanding the offering for the growing patient community has always been a clear goal for the company. He added, “Our new CannaPoints program serves to guide our patients on their medical cannabis journey and provide additional support as needed.”
Tilray Medical already has a broad portfolio of medical cannabis brands in North America, but the team is working around the clock to go the extra mile. Considering that patients’ needs are incomprehensible, Tilray Medical’s latest move to differentiate high-quality brands stands out from the competition. Its wide range of cannabidiol (CBD) and tetrahydrocannabinol (THC) products has come to meet the needs of this large portfolio of customers.
To make the journey into the world of medical cannabis much easier, Tilray Medical has joined forces with Strainprint, a mobile app focused on medical cannabis tracking. The purpose of this partnership is to create the CannaPoints program. Patients of this brand, in company with the advice of a physician, can use the new program to explore more and new offerings.
At the same time, many will be able to explore new offerings, learn more about the details of the strain and record the effects, making it easier for them to develop personal consumption programs at a more appropriate level. The app is available for free on the App Store or Google Play for Apple and Android devices.